Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Return on Equity (2016 - 2025)

Historic Return on Equity for Karyopharm Therapeutics (KPTI) over the last 13 years, with Q4 2025 value amounting to 0.7%.

  • Karyopharm Therapeutics' Return on Equity rose 2500.0% to 0.7% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.7%, marking a year-over-year increase of 2500.0%. This contributed to the annual value of 0.82% for FY2025, which is 3400.0% up from last year.
  • According to the latest figures from Q4 2025, Karyopharm Therapeutics' Return on Equity is 0.7%, which was up 2500.0% from 0.49% recorded in Q3 2025.
  • Karyopharm Therapeutics' Return on Equity's 5-year high stood at 5.14% during Q1 2023, with a 5-year trough of 36.82% in Q1 2021.
  • Moreover, its 5-year median value for Return on Equity was 1.0% (2024), whereas its average is 0.5%.
  • As far as peak fluctuations go, Karyopharm Therapeutics' Return on Equity plummeted by -350900bps in 2021, and later soared by 381400bps in 2022.
  • Karyopharm Therapeutics' Return on Equity (Quarter) stood at 1.21% in 2021, then surged by 75bps to 2.12% in 2022, then tumbled by -43bps to 1.21% in 2023, then plummeted by -63bps to 0.44% in 2024, then surged by 58bps to 0.7% in 2025.
  • Its Return on Equity stands at 0.7% for Q4 2025, versus 0.49% for Q3 2025 and 0.56% for Q2 2025.